Evolution of phage display technology: from discovery to application

Rahbarnia, Leila; Farajnia, Safar; Babaei, Hossein; Majidi, Jafar; Veisi, Kamal; Ahmadzadeh, Vahideh; Akbari, Bahman

doi:10.1080/1061186x.2016.1258570

Cited by 56 publications

(43 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Phage display is one of the most commonly used methods for in vitro peptide‐screening . Many types of phage can be used in phage display technique, including filamentous bacteriophage, T4 phage, T7 phage, Qβ phage, etc . To be displayed on phage particles, cyclic peptides should be fused to solvent‐exposed surface proteins, such as pIII, pVI, pVII, pVIII, and pIX proteins .…”

Section: Strategies To Develop Cyclic Peptides Into Therapeutic Agentsmentioning

confidence: 99%

A gold mine for drug discovery: Strategies to develop cyclic peptides into therapies

Jing

Jin

2019

Medicinal Research Reviews

121

130

View full text Add to dashboard Cite

As a versatile therapeutic modality, peptides attract much attention because of their great binding affinity, low toxicity, and the capability of targeting traditionally “undruggable” protein surfaces. However, the deficiency of cell permeability and metabolic stability always limits the success of in vitro bioactive peptides as drug candidates. Peptide macrocyclization is one of the most established strategies to overcome these limitations. Over the past decades, more than 40 cyclic peptide drugs have been clinically approved, the vast majority of which are derived from natural products. The de novo discovered cyclic peptides on the basis of rational design and in vitro evolution, have also enabled the binding with targets for which nature provides no solutions. The current review summarizes different classes of cyclic peptides with diverse biological activities, and presents an overview of various approaches to develop cyclic peptide‐based drug candidates, drawing upon series of examples to illustrate each strategy.

show abstract

Section: Strategies To Develop Cyclic Peptides Into Therapeutic Agentsmentioning

confidence: 99%

A gold mine for drug discovery: Strategies to develop cyclic peptides into therapies

Jing

Jin

2019

Medicinal Research Reviews

121

130

View full text Add to dashboard Cite

show abstract

“…At present, two main strategies for developing mAbs are used including animal immunization and surface display methodologies such phage display technology (McCafferty et al 1990) (Rahbarnia et al 2017b).…”

Section: Antibody Therapy Against Infectious Diseasesmentioning

confidence: 99%

“…Antibody phage display technology is an in vitro screening process independent from any immune system in which the antibody fragments are displayed in phages surface (Rahbarnia et al 2017a). For instance, human scFv phage library with high diversity of gene repertoires provides a rich source of scFvs to almost any antigen (Rahbarnia et al 2017b).…”

Section: Antibody Therapy Against Infectious Diseasesmentioning

confidence: 99%

Current trends in targeted therapy for drug-resistant infections

Rahbarnia

Farajnia

Naghili

et al. 2019

Appl Microbiol Biotechnol

Self Cite

View full text Add to dashboard Cite

Escalating antibiotic resistance is now a serious menace to global public health. It may be led to the emergence of "postantibiotic age" in which most of infections are untreatable. At present, there is an essential need to explore novel therapeutic strategies as a strong and sustainable pipeline to combat antibiotic-resistant infections. This review focuses on recent advances in this area including therapeutic antibodies, antimicrobial peptides, vaccines, gene therapy, genome editing, and phage therapy for tackling drug-resistant infections.

show abstract

“…Phage display is a library method which permits screening of antibodies from a large recombinant library (Falkowska et al, 2014;Boots et al, 1997;Chan et al, 1996;Aghebati-Maleki et al, 2017;Rahbarnia et al, 2017;Finlay et al, 2017). Antibodies can be displayed in the form of either single chain variable fragments (ScFv) or antigen-binding fragments (Fab).…”

Section: Phage/yeast Displaymentioning

confidence: 99%

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies

Sun

Yan

Tang³

et al. 2018

Virus Research

View full text Add to dashboard Cite

HIV/AIDS has become a worldwide pandemic. Before an effective HIV-1 vaccine eliciting broadly neutralizing monoclonal antibodies (bnmAbs) is fully developed, passive immunization for prevention and treatment of HIV-1 infection may alleviate the burden caused by the pandemic. Among HIV-1 infected individuals, about 20% of them generated cross-reactive neutralizing antibodies two to four years after infection, the details of which could provide knowledge for effective vaccine design. Recent progress in techniques for isolation of human broadly neutralizing antibodies has facilitated the study of passive immunization. The isolation and characterization of large panels of potent human broadly neutralizing antibodies has revealed new insights into the principles of antibody-mediated neutralization of HIV. In this paper, we review the current effective techniques in broadly neutralizing antibody isolation.

show abstract

Evolution of phage display technology: from discovery to application

Cited by 56 publications

References 99 publications

A gold mine for drug discovery: Strategies to develop cyclic peptides into therapies

A gold mine for drug discovery: Strategies to develop cyclic peptides into therapies

Current trends in targeted therapy for drug-resistant infections

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies

Contact Info

Product

Resources

About